Literature DB >> 33639995

Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF.

Francesco Bonella1, Ilaria Campo2, Michele Zorzetto3, Eda Boerner4, Shinichiro Ohshimo5, Dirk Theegarten6, Christian Taube4, Ulrich Costabel4.   

Abstract

BACKGROUND: Genetic variants of TOLLIP and MUC5B, both on chromosome 11, have been reported to be associated with the development and/or prognosis of idiopathic pulmonary fibrosis (IPF). This retrospective study was conducted to investigate the association of MUC5B and TOLLIP SNPs with disease outcome in IPF. 62 IPF patients and 50 healthy controls (HC) from our Institution were genotyped for SNPs within MUC5B (rs35705950) and TOLLIP (rs3750920 and rs5743890). Correlation of SNPs genotypes with survival, acute exacerbation (AE) or disease progression (defined as a decline of ≥ 5% in FVC and or ≥ 10% in DLco in one year) was investigated.
RESULTS: The MUC5B rs35705950 minor allele (T) was more frequent in IPF subjects than in HC (35% vs 9% p < 0.001). TOLLIP SNPs alleles and genotype distribution did not differ between IPF and HC and did not vary according to gender, age, BMI and lung functional impairment at baseline. The minor allele (C) in TOLLIP rs5743890 was associated with worse survival and with disease progression in all performed analyses. The MUC5B rs35705950 or the TOLLIP rs3750920 minor allele, were not associated with disease progression or AE.
CONCLUSION: We confirm that the minor allele of MUC5B rs35705950 is associated with IPF. The minor allele of TOLLIP rs5743890 appears to be a predictor of worse survival and more rapid disease progression, therefore being of potential utility to stratify IPF patients at baseline.

Entities:  

Keywords:  Disease progression; IPF; MUC5B; TOLLIP

Mesh:

Substances:

Year:  2021        PMID: 33639995      PMCID: PMC7913255          DOI: 10.1186/s13023-021-01750-3

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  31 in total

1.  Intracellular trafficking of interleukin-1 receptor I requires Tollip.

Authors:  Brian Brissoni; Laetitia Agostini; Michel Kropf; Fabio Martinon; Valentin Swoboda; Saskia Lippens; Helen Everett; Natalia Aebi; Sophie Janssens; Etienne Meylan; Michela Felberbaum-Corti; Harald Hirling; Jean Gruenberg; Jürg Tschopp; Kimberly Burns
Journal:  Curr Biol       Date:  2006-11-21       Impact factor: 10.834

2.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.

Authors:  Hude Quan; Bing Li; Chantal M Couris; Kiyohide Fushimi; Patrick Graham; Phil Hider; Jean-Marie Januel; Vijaya Sundararajan
Journal:  Am J Epidemiol       Date:  2011-02-17       Impact factor: 4.897

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 4.  Facts and promises on lung biomarkers in interstitial lung diseases.

Authors:  Ilaria Campo; Michele Zorzetto; Francesco Bonella
Journal:  Expert Rev Respir Med       Date:  2015-07-04       Impact factor: 3.772

5.  Toll-interacting protein differentially modulates HIF1α and STAT5-mediated genes in fibroblasts.

Authors:  Elizabeth Kowalski; Shuo Geng; Allison Rathes; Ran Lu; Liwu Li
Journal:  J Biol Chem       Date:  2018-06-19       Impact factor: 5.157

6.  Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias.

Authors:  Joanne J van der Vis; Reinier Snetselaar; Karin M Kazemier; Liesbeth ten Klooster; Jan C Grutters; Coline H M van Moorsel
Journal:  Respirology       Date:  2015-12-24       Impact factor: 6.424

7.  Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis.

Authors:  Carmel J Stock; Hiroe Sato; Carmen Fonseca; Winston A S Banya; Philip L Molyneaux; Huzaifa Adamali; Anne-Marie Russell; Christopher P Denton; David J Abraham; David M Hansell; Andrew G Nicholson; Toby M Maher; Athol U Wells; Gisela E Lindahl; Elisabetta A Renzoni
Journal:  Thorax       Date:  2013-01-15       Impact factor: 9.139

8.  Predicting pulmonary fibrosis disease course from past trends in pulmonary function.

Authors:  Shelley L Schmidt; Nabihah Tayob; Meilan K Han; Christopher Zappala; Dolly Kervitsky; Susan Murray; Athol U Wells; Kevin K Brown; Fernando J Martinez; Kevin R Flaherty
Journal:  Chest       Date:  2014-03-01       Impact factor: 9.410

9.  Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis.

Authors:  Francesco Bonella; Shinichiro Ohshimo; Cai Miaotian; Matthias Griese; Josune Guzman; Ulrich Costabel
Journal:  Orphanet J Rare Dis       Date:  2013-04-04       Impact factor: 4.123

Review 10.  The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population.

Authors:  Raphael Borie; Bruno Crestani; Philippe Dieude; Hilario Nunes; Yannick Allanore; Caroline Kannengiesser; Paolo Airo; Marco Matucci-Cerinic; Benoit Wallaert; Dominique Israel-Biet; Jacques Cadranel; Vincent Cottin; Steven Gazal; Anna L Peljto; John Varga; David A Schwartz; Dominique Valeyre; Bernard Grandchamp
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more
  3 in total

1.  DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study.

Authors:  Martina Doubkova; Eva Kriegova; Simona Littnerova; Petra Schneiderova; Martina Sterclova; Vladimir Bartos; Martina Plackova; Monika Zurkova; Radka Bittenglova; Vladimira Lostaková; Lenka Siskova; Pavlina Lisa; Hana Suldova; Michael Doubek; Jana Psikalova; Tomas Snizek; Pavlina Musilova; Martina Vasakova
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

2.  The minor T allele of the MUC5B promoter rs35705950 associated with susceptibility to idiopathic pulmonary fibrosis: a meta-analysis.

Authors:  Xiaozheng Wu; Wen Li; Zhenliang Luo; Yunzhi Chen
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

Review 3.  Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions.

Authors:  Anna Stainer; Paola Faverio; Sara Busnelli; Martina Catalano; Matteo Della Zoppa; Almerico Marruchella; Alberto Pesci; Fabrizio Luppi
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.